IHH 3Q robust ops hurt by financing


The proposed acquisition of Prince Court Medical Centre could further increase bill intensity and volume from FY20F.

KUALA LUMPUR: IHH Healthcare core net profit for the nine months ended Sept 30,2019 of RM630.8mil (-8.0% yoy) was below expectations, CGS-CIMB Equities Research said.

“Without currency and MFRS 16 effects, 3Q19 EBITDA grew by 22% yoy, ” it said on Monday.

Most markets saw higher revenue intensity and more foreign patients, while overall volume was weaker in Acibadem and GHK.

“Maintain Add on valuation two standard deviation below mean and faster GHK/Fortis ramp-up, ” it said.

CGS-CIMB Research said IHH reported 3Q19 headline PATMI of RM236.3m, reversing from 3Q18 net loss of RM104.1m.

“Excluding one-off items of RM24.6m FV loss in FX interest rate swaps and RM83.4m FX gain on borrowings, 3Q19 underlying PATMI would have dropped 34.5% yoy to RM202.3m.

“9M19 core PATMI of RM630.8m (-8.0% yoy) was a miss against our/ consensus at 65%/64% of full-year forecasts, on higher depreciation and financing costs (additional loans and refinancing into swaps).

“In constant currency terms and excluding MFRS 16 effects, 3Q19 revenue and EBITDA rose 36% and 22% yoy, respectively, ” it said.

CGS-CIMB Research said Malaysia saw exceptional patient load growth of 14.9% in 3Q19, which IHH attributed to organic efforts, more foreign patients and the acquisition of Amanjaya in Oct 2018.

The proposed acquisition of Prince Court Medical Centre could further increase bill intensity and volume from FY20F.

Singapore benefitted from medical tourism (mainly Indonesians) and a better case mix, resulting in EBITDA margin improvement to 32.9% (2Q19: 27.6%, 3Q18: 30.6%).

Inpatient admissions in Acibadem fell for the 2nd consecutive quarter (-6.1% yoy), led by fewer patients under the local social insurance scheme, which did not affect the revenue intensity per patient (+12.3% yoy).

Initiatives to refinance the US$170m non-lira debt has helped mitigate FX volatility, though average interest cost is higher due to the conversion into FX swaps.

Gleneagles Hong Kong (GHK) saw lower patient footfall and bed occupancy (3Q19: 58%) due to political unrest, but continues to narrow EBITDA loss to RM39.4m from 3Q18’s RM49.4m on higher revenue intensity.

Gleneagles Chengdu opened 100 beds in Oct 19, with 24 doctors and c.200 employees across various specialties (paediatrics, gynae, ENT, gastro, etc.)

“ We cut our FY19-21F EPS by 13.0-18.0% on higher depreciation and financing costs, resulting in a lower SOP-based TP to RM6.06 even as we roll forward our valuation to end-CY20F.

“As the share price has recently retraced, we think its valuation is now more palatable at 15.1x FY21F EV/EBITDA, more than two standard deviations below its historical mean.

“Maintain Add, with a faster ramp-up of GHK and Fortis as potential catalysts. Although Fortis posted its 3rd quarter of operational pre-tax profit, we think the pending court case against IHH/Fortis could be a near-term overhang on the share price, ” it said.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights

IHH Healthcare , Prince Court , currency , MFRS 16

   

Next In Business News

Serba Dinamik says to take legal action against auditor KPMG
Daibochi reports steady Q3 results, warns rising costs may impact prospect�
Genting, Digi underpin FBM KLCI rebound
Pay-TV company Astro delivers nearly double net profit in Q1
BNM's international reserves rise to US$111bil as at June 15
Oil rises on optimism of quick recovery in global demand
Chipmaker GlobalFoundries plans US$6bil expansion in Singapore, US, Germany
RHB Group's green financing grows to RM3.25bil YTD
Affin, Generali to co-develop more than RM2bil GWP insurance business
Yenher to expand presence in overseas market within 24 months after listing

Stories You'll Enjoy


Vouchers